NY-SOUNDTRAP
6.10.2020 14:02:19 CEST | Business Wire | Press release
Soundtrap today launched Soundtrap Capture , a collaborative mobile app for on-the-go music capture and creation. Built with musicians and artists in mind, the new app is an interactive, user-friendly tool that lets creators collaborate in real time, and record high-quality audio whenever and wherever inspiration strikes. Starting today, Soundtrap Capture is available globally to download for free on the iOS App Store .
“This new app is all about capturing creativity whenever, and wherever it strikes. Whether it’s walking down the street, sitting in a cafe or jamming in the studio - the Soundtrap Capture app lets artists collaborate and create right there in the moment.” - Per Emanuelsson, Director of Soundtrap at Spotify.
Soundtrap empowers high-quality collaborative music-making for people around the world, giving creators the opportunity to jam in one place - see who’s recording, vibe to ideas and discuss and react to them in real time. With the Soundtrap Capture app, turning concepts into songs has never been easier.
Developed in conjunction with artists, Soundtrap Capture is an artist-oriented experience focused on the very first step of the music creation process: the concept. It’s this early stage of the creative process - the first strains of melody, the initial ad-libbed verse, the spontaneous guitar riff - that Soundtrap aims to streamline through Soundtrap Capture.
Based on insights from thousands of musicians and their collaborators, Soundtrap set out to simplify the overly complicated music ideation process, which typically involves many musicians toggling between voice notes, messaging apps, digital audio workstations and storage destinations to get their concepts across. Equipped with built-in tools for recording, layering, real-time collaboration and storage, Soundtrap Capture replaces this multi-platform process with one efficient app.
“Empowering artists to create their best work is core to our mission at Spotify,” said Charlie Hellman, Vice President and Head of Marketplace, Spotify. “I'm excited to see Soundtrap Capture help more musicians simplify the creative process and capture sparks of inspiration.”
With an upcoming update, Soundtrap’s Studio tool will soon allow artists to collaborate seamlessly on projects between the Soundtrap Capture app and the Soundtrap Studio app on mobile or desktop. This zero-friction workflow will enable, for example, a musician to start an idea on the go via Soundtrap Capture, and then have a collaborator pick up and build on that idea using Soundtrap Studio from their computer.
Features immediately available on Soundtrap Capture include:
- Multi-track Layering: layer track recordings, instruments and vocals over one another to create different takes.
- Collaborate with Creators: invite multiple collaborators to join a project, present ideas, record and layer tracks to create songs together in real time.
- Live Storage: immediately sync and back up all projects to the Soundtrap system, and easily access them so that you never lose an idea again.
And coming later this year:
- Seamless Integration: transfer seamlessly between the Soundtrap Capture app and the Soundtrap Studio, between desktop and mobile, all without missing a beat.
ABOUT SOUNDTRAP
A part of Spotify, Soundtrap is the first cloud-based recording platform for music and podcasts that works on all operating systems, enabling people to collaborate and record together wherever they are. With an easy-to-use creation platform, Soundtrap empowers creators to build original content using a combination of software instruments, real instruments and audio recording. For more information, please visit https://www.soundtrap.com .
MEDIA ASSETS
Available for download HERE .
View source version on businesswire.com: https://www.businesswire.com/news/home/20201006005238/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen Consulting tilføjer samarbejdsfirmaet TechSparq25.10.2026 06:09:00 CET | Pressemeddelelse
Andersen Consulting udvider sine kompetencer inden for teknologi og forretningstransformation gennem en samarbejdsaftale med TechSparq, en amerikansk virksomhed, der kombinerer strategi, commerce engineering og ai med praktisk implementering. TechSparq er et digitalt konsulenthus, der tilbyder strategi- og rådgivningstjenester, commerce engineering samt tjenester inden for ai og agentbaseret handel til virksomheder inden for detailhandel og forbrugsgoder, luksus og mode samt e-handel og direkte salg til forbrugere. Virksomheden har hovedkontor i Oregon og kombinerer strategisk planlægning med praktisk implementering for at hjælpe kunderne med at udvikle deres digitale initiativer, kundeoplevelse og driftsmodeller. "Vi etablerede vores virksomhed for at bygge bro mellem dem, der udvikler strategien, og dem, der har ansvaret for at føre den ud i livet," udtalte Dedrick Boyd, stifter af og administrerende direktør for TechSparq. "Vores samarbejde med Andersen Consulting giver os mulighed
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press release
Potential first-in-class GPC3 x 4-1BB bispecific achieves a 36% confirmed response rate at Phase 3 dose and favorable safety profile in heavily pretreated liver cancerBrain-penetrant PRMT5 inhibitor shows promising antitumor and CNS activity in the largest publicly shared MTAP-deficient datasetFirst clinical data of CEA-targeting ADC demonstrates encouraging and sustained responses in CEAhigh NSCLC BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to dise
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom